Natalizumab treatment for multiple sclerosis: updates and considerations for safer treatment in JCV positive patients. [electronic resource]
Producer: 20150407Description: 960-5 p. digitalISSN:- 1678-4227
- Adult
- Antibodies, Monoclonal, Humanized -- adverse effects
- DNA, Viral
- Female
- Humans
- Immunosuppressive Agents -- adverse effects
- JC Virus -- genetics
- Leukoencephalopathy, Progressive Multifocal -- immunology
- Multiple Sclerosis -- drug therapy
- Natalizumab
- Risk Assessment
- Risk Factors
- Time Factors
- Treatment Outcome
- Viral Load
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.